May 7, 2020 / 7:05 AM / 2 months ago

BRIEF-Recipharm Q1 EBITDA Up At SEK 431 Million

May 7 (Reuters) - Recipharm AB (publ):

* PUBLISHES ITS INTERIM REPORT JANUARY-MARCH 2020

* Q1 EBITDA SEK 431 MILLION VERSUS SEK 291 MILLION YEAR AGO

* Q1 NET SALES SEK 2.59 BILLION VERSUS SEK 1.81 BILLION YEAR AGO

* AFTER PREVIOUSLY ANNOUNCED EQUITY ISSUES OF APPROXIMATELY SEK 2.5 BILLION, LEVERAGE WILL AGAIN BE AT AN ACCEPTABLE LEVEL

* LONG-TERM PROSPECTS REMAIN UNCHANGED.

* IN SHORT TO MEDIUM TERM, LIKE MOST ACROSS INDUSTRY AND WIDER, WE FACE SIGNIFICANT UNCERTAINTY Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below